Herpes and demographic factors in patients treated at the Ecuadorian Institute of Social Security Jipijapa, 2022– 2024
DOI:
https://doi.org/10.62305/biosana.v6i2.1009Keywords:
antibodies; epidemiology; prevalence; seropositivity; transmissionAbstract
Herpes is one of the most common chronic viral infections in the human population and is by caused by herpes simplex viruses type 1 and type 2, which have the ability to remain latent. The general objective of this study was to analyze herpes infection and demographic factors in patients treated at the Ecuadorian Institute of Social Security Jipijapa. The methodology consisted of a retrospective, cross-sectional, and quantitative study that included 348 patients treated during the period 2022-2024. The results showed that Table 1 indicates the most representative age groups were 38–47 years with 135 cases (38.79%) and 28–37 years old with 126 cases (36.21%), concentrating 74.7%; Table 2, which analyzes the frequency of herpes simplex virus type 1 Immunoglobulin M, revealed an overall percentage of 6.60%, women were significantly older (87.0%); Table 3 of the prevalence showed that herpes 1 had a low overall prevalence (6.60%); Table 4 found that, in women, the four types of antibodies show P values < 0.05, indicating a significant association, in men, the Immunoglobulin M of herpes 2 has a significant value (p = 0.046), the rest are not significant (p > 0.05). It was concluded that there was a marked gender bias with a predominance of female patients. The identified cases revealed an epidemiological pattern characterized by female predominance. The specific prevalence of HSV-1 was 6.60%, while HSV-2 represented 9.19% of the studied population. Additionally, an association between age and case distribution was observed.
Downloads
References
Birkmann A, Saunders R. Overview on the management of herpes simplex virus infections: Current therapies and future directions. Antiviral Res. 2025; 23(7): p. 106152.
Organizacion Mundial de la Salud. Virus del herpes simple. [Online]; 2024. Acceso 23 de Mayode 2025. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/herpes-simplex-virus.
de Oliveira F, Melo L, Croda J et al. High silent prevalence of human herpesvirus 1 (HSV-1) infection affecting the indigenous reservation of the municipality of Dourados, Central-West Brazil. BMC Infectious Diseases volume. 2024; 24(700).
Tutasig K. Síndrome torch: enfoque racional del diagnóstico y tratamiento pre y post natal en el Ecuador. SOCIENCYTEC. 2023; 1(1).
Serrano R. Prevalencia de infecciones TORCH en mujeres embarazadas del cantón Olmedo: Un llamado a la prevención y control. Estudios Y Perspectivas Revista Científica Y Académica. 2023; 3(1): p. 174–194.
Chilan G, Zambrano K, Peñaherrera M et al. Seroprevalencia a herpesvirus y sus factores de riesgo en mujeres ecuatorianas en edad reproductiva. Dominio de ciencias. 2020; 5(2): p. 81-88.
Gonzales F, Torres C, Pinos J et al. Diagnostic screening of HPV genotypes in 555 Ecuadorian mestizo women of seven provinces, and comparison with other Latino American populations. Universidad de Manizales. 2020; 20(1): p. 86-96.
Khadr L, Harfouche M, Omori R et al. The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions. Clin Infect Dis. 2020; 68(5): p. 757–772.
Alareeki A, Osman A, Khandakji M et al. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health Eur. 2022 ; 25: p. 100558.
Nasrallah G, Dargham S, Al-Sadeq D et al. Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar. Virology Journal. 2023; 20(188).
Looker K, Welton N, Sabin K et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. The Lancet Infectious Diseases. 2020; 20(2): p. 240-249.
Choi S, Kim D. Epidemiologic and Etiological Features of Korean Patients With Behçet’s Disease. J Rheum Dis. 2021 ; 28(4): p. 183–191.
Pillay R, Naidoo P, Mkhize Z. Herpes simplex virus type 2 in sub-Saharan Africa and the potential impact of helminth immune modulation. Front. Cell. Infect. Microbiol. 2024; 14(24).
Ortiz J, Vega B, Campoverde A et al. Human Papillomavirus Prevalence and Associated Factors in Indigenous Women in Ecuador: A Cross-Sectional Analytical Study. Infect Dis Rep. 2023 ; 15(3): p. 267–278.
Harfouche M, Maalmi H, Abu L. Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta-analyses and metaregressions. Sex Transm Infect. 2021 ; 97(7): p. 490–500.
Magdaleno J, Hernandez P, Valenzuela C et al. Genital Infection With Herpes Simplex Virus Type 1 and Type 2 in Valencia, Spain: A Retrospective Observational Study. Actas dermos-sifiliogicas. ; 111(1): p. 53-58.
Deka S, Khumar M, Gupta P et al. A Contemporary Insight Into the Seroepidemiology of Herpes Simplex Virus Infection in the Sub-Himalayan Region. ScientificWorldJournal. 2025 ; 25: p. 6826627.
Toignet A, Tchounga S, Taheu Ch et al. Herpes Simplex Virus Type-2 Seroprevalence and Risk Factors Among Pregnant Women at Etoudi Marie Reine Medical Centre, Yaoundé-Cameroon. EJMED. 2025; 7(2).
Riyad K, Hussein N, Alsaffar R et al. Prevalence of herpes simplex virus types 1 and 2 antibodies among individuals screened in a tertiary hospital in the Eastern province of Saudi Arabia. J Med Life. 2022 ; 15(10): p. 1272–1277.
Fu H, Yu H, Zhao Y et al. Association between hypertension and the prevalence of liver steatosis and fibrosis. BMC Endocr Disord. 2023; 23(1): p. 85.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 BIOSANA Health Scientific Journal. ISSN 2960-8481
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
